Streetbeat News

Price Targets

LAD

Wells Fargo analyst Colin Langan has maintained an Equal-Weight rating on Lithia Motors (NYSE:LAD) and lowered the price target from $275 to $259.

Portfolio Pulse from Benzinga Newsdesk

October 26, 2023 | 12:49 pm

TMO

Morgan Stanley analyst Tejas Savant has maintained an Overweight rating on Thermo Fisher Scientific (NYSE:TMO) but lowered the price target from $600 to $545.

Portfolio Pulse from Benzinga Newsdesk

October 26, 2023 | 12:35 pm

NOW

Morgan Stanley analyst Keith Weiss maintains an Overweight rating on ServiceNow (NYSE:NOW) and has raised the price target from $630 to $648.

Portfolio Pulse from Benzinga Newsdesk

October 26, 2023 | 12:33 pm

SEIC

Morgan Stanley analyst Rayna Kumar maintains an Underweight rating on SEI Inv (NASDAQ:SEIC) and has lowered the price target from $63 to $61.

Portfolio Pulse from Benzinga Newsdesk

October 26, 2023 | 12:32 pm

ODFL

Morgan Stanley analyst Ravi Shanker has maintained an Equal-Weight rating on Old Dominion Freight Line (NASDAQ:ODFL) and raised the price target from $358 to $360.

Portfolio Pulse from Benzinga Newsdesk

October 26, 2023 | 12:31 pm

NSC

Morgan Stanley analyst Ravi Shanker has maintained an Equal-Weight rating on Norfolk Southern (NYSE:NSC) and lowered the price target from $174 to $170.

Portfolio Pulse from Benzinga Newsdesk

October 26, 2023 | 12:30 pm

MCO

Morgan Stanley analyst Toni Kaplan has maintained an Equal-Weight rating on Moody's (NYSE:MCO) and lowered the price target from $332 to $318.

Portfolio Pulse from Benzinga Newsdesk

October 26, 2023 | 12:29 pm

MAT

Morgan Stanley analyst Megan Alexander has maintained an Overweight rating on Mattel (NASDAQ:MAT) but lowered the price target from $27 to $25.

Portfolio Pulse from Benzinga Newsdesk

October 26, 2023 | 12:27 pm

KLAC

Morgan Stanley analyst Joseph Moore has maintained an Equal-Weight rating on KLA (NASDAQ:KLAC) and lowered the price target from $529 to $500.

Portfolio Pulse from Benzinga Newsdesk

October 26, 2023 | 12:27 pm

IART

Morgan Stanley analyst Drew Ranieri has maintained an 'Underweight' rating on Integra Lifesciences (NASDAQ:IART) and lowered the price target from $44 to $37.

Portfolio Pulse from Benzinga Newsdesk

October 26, 2023 | 12:25 pm